China-Asia Stocks

[sweet crude]

CBPC - bird flu & Influenza play

BIRD FLU TESTING (has copy of deadly H5N1 virus)

Avian (“Bird Flu”) H5N1 Virus – By February 2004, the avian or “bird” flu spread across 10 countries in Asia and caused dozens of deaths in Thailand and Vietnam. In China, the bird flu affected more than half of all provinces and territories. CBPC stands to be a major player in creating and mass-producing a vaccine for a potential pandemic bird flu outbreak. In June 2006, China Biopharma received a copy of the H5N1 virus (a deadly virus transmitted from bird to human), and has begun animal testing on a vaccine.

http://chinabiopharma.net/index_4.asp


INVESTMENT HIGHLIGHTS

- Market Growth – the market in China for flu vaccinations has grown from 3.9 million doses in 2000 to 22.3 million doses in 2005, or 30% year over year.
- Distribution Network – the company has the largest independent vaccine distribution network covering 268 cities in China.
- Strategic Alliances – the company retains a close relationship with the Chinese Center of Disease Control (CDC), providing local CDC vaccinations, and providing their high-capacity production facility for any potential epidemics within China.
- Product Pipeline – in addition to marketing vaccines for Influenza, Epidemic Hemorrhagic Fever, and Epidemic Japanese Encephalitis, the company is also conducting research such new products to cover allergies and avian bird flu.
- Revenue Projection – management anticipates generating $10 million in annual revenues and positive net income for fiscal year 2006.
- Management Experience – the company retains some of the top scientists within the human vaccine fields in China, and has had a number of years experience running a public company